Cambridge biotech Repertoire Immune Medicines has completed a $189 million Series B financing. The company is focused on decoding the immune synapse to create novel immune therapies for cancer, immune disorders, infectious disease, and other serious diseases. Proceeds from this financing will support further expansion of the company’s proprietary DECODE discovery platform, accelerate its clinical […]

Sage Therapeutics and Biogen have reported topline results from the Phase 2 KINETIC Study evaluating SAGE-324 in the treatment of people with essential tremor (ET). The study achieved its primary endpoint of a statistically significant reduction from baseline compared to placebo. “We are encouraged by the positive results of the KINETIC Study, which indicate that […]

Johnson & Johnson has announced that it is assuming full responsibility regarding the manufacturing of drug substance for its COVID-19 vaccine at contract manufacturer Emergent BioSolutions Maryland facility. Specifically, J&J is adding dedicated leaders for operations and quality, and significantly increasing the number of manufacturing, quality and technical operations personnel to work with the company’s […]

Aveo Oncology has announced FDA approval for Fotivda (tivozanib) for the treatment of adults with renal cell carcinoma (RCC) who meet certain treatment guidelines. Fotivda is a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and was approved in August 2017 in the European Union and other EUSA countries. According to the American Cancer Society, renal cell […]

ElevateBio has raised $525 million in a Series C financing. According to its website, the company has created a business model addressing the most pressing challenges in the field of cell and gene therapy. Its suite of technologies includes gene editing, induced pluripotent stem cells, and protein, viral, and cellular engineering. With this financing, ElevateBio […]

On March 31, following reports in the New York Times and other media sources regarding coronavirus vaccine quality issues at its manufacturing partner Emergent BioSolutions, J & J released an official statement, excerpted below: Since January of 2020, Johnson & Johnson has been working directly with governments, health authorities and other companies to help end […]

Bristol Myers Squibb and Cambridge-based bluebird bio have announced FDA approval for Abecma, a personalized immune cell therapy for the treatment of certain patients with multiple myeloma. As an anti-BCMA CAR T cell therapy, Abecma recognizes and binds to BCMA, a protein that is nearly universally expressed on cancer cells in multiple myeloma, leading to the death of […]